Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells

Molecular and Cellular Endocrinology

Volumn 342, Issue 1-2, 2011, Pages 20-31

  Buchanan, Grant ^a,b   Need, Eleanor F ^b   Barrett, Jeffrey M ^b   Bianco Miotto, Tina ^b   Thompson, Vanessa C ^b   Butler, Lisa M ^b   Marshall, Villis R ^c   Tilley, Wayne D ^b   Coetzee, Gerhard A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Androgen receptor; Corepressor; NCoR; Polyglutamine; Prostate cancer risk; SMRT

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR AGONIST; ANDROGEN RECEPTOR ANTAGONIST; FACTOR AF2; HORMONE RECEPTOR STIMULATING AGENT; POLYGLUTAMINE; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CAG REPEAT; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; GENE ACTIVITY; GENE DELETION; GENE INTERACTION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENETIC POLYMORPHISM; HORMONE RESPONSE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; RESIDUE ANALYSIS; SIGNAL TRANSDUCTION; TRANSACTIVATION; WILD TYPE;

ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; CO-REPRESSOR PROTEINS; MALE; MUTATION; NUCLEAR RECEPTOR CO-REPRESSOR 2; PEPTIDES; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, ANDROGEN; REPETITIVE SEQUENCES, NUCLEIC ACID; TRANSCRIPTIONAL ACTIVATION;

EID: 79960847025     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.05.023     Document Type: Article

References (82)

1. Albertelli M.A., O'Mahony O.A., Brogley M., Tosoian J., Steinkamp M., Daignault S., Wojno K., Robins D.M. Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice. Hum. Mol. Genet. 2008, 17:98-110.
2. Alen P., Claessens F., Verhoeven G., Rombauts W., Peeters B. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol. Cell. Biol. 1999, 19:6085-6097.
3. Battaglia S., Maguire O., Campbell M.J. Transcription factor co-repressors in cancer biology: roles and targeting. Int. J. Cancer. 2010, 126:2511-2519.
4. Beilin J., Ball E., Favaloro J., Zajac J. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J. Mol. Endocrinol. 2000, 25:85-96.
5. Berrevoets C.A., Doesburg P., Steketee K., Trapman J., Brinkmann A.O. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol. Endocrinol. 1998, 12:1172-1183.
6. Biddie S.C., John S., Hager G.L. Genome-wide mechanisms of nuclear receptor action. Trends Endocrinol. Metab. 2010, 21:3-9.
7. Birrell S.N., Butler L.M., Harris J.M., Buchanan G., Tilley W.D. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. 2007, 21:2285-2293.
8. Bolton E.C., So A.Y., Chaivorapol C., Haqq C.M., Li H., Yamamoto K.R. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 2007, 21:2005-2017.
9. Buchanan G., Birrell S.N., Peters A.A., Bianco-Miotto T., Ramsay K., Cops E.J., Yang M., Harris J.M., Simila H.A., Moore N.L., Bentel J.M., Ricciardelli C., Horsfall D.J., Butler L.M., Tilley W.D. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res. 2005, 65:8487-8496.
10. Buchanan G., Craft P.S., Yang M., Cheong A., Prescott J., Jia L., Coetzee G.A., Tilley W.D. PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate 2004, 60:352-366.
11. Buchanan G., Irvine R.A., Coetzee G.A., Tilley W.D. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev. 2001, 20:207-223.
12. Buchanan G., Ricciardelli C., Harris J.M., Prescott J., Yu Z.C., Jia L., Butler L.M., Marshall V.R., Scher H.I., Gerald W.L., Coetzee G.A., Tilley W.D. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res. 2007, 67:10087-10096.
13. Buchanan G., Yang M., Cheong A., Harris J.M., Irvine R.A., Lambert P.F., Moore N.L., Raynor M., Neufing P.J., Coetzee G.A., Tilley W.D. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum. Mol. Genet. 2004, 13:1677-1692.
14. Buchanan G., Yang M., Harris J.M., Nahm H.S., Han G., Moore N., Bentel J.M., Matusik R.J., Horsfall D.J., Marshall V.R., Greenberg N.M., Tilley W.D. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol. Endocrinol. 2001, 15:46-56.
15. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., Eeckhoute J., Shao W., Hestermann E.V., Geistlinger T.R., Fox E.A., Silver P.A., Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122:33-43.
16. Chang C.Y., McDonnell D.P. Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol. Endocrinol. 2002, 16:647-660.
17. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
18. Chen J.D., Evans R.M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995, 377:454-457.
19. Chen J.D., Umesono K., Evans R.M. SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. Proc. Natl. Acad. Sci. U S A. 1996, 93:7567-7571.
20. Chmelar R., Buchanan G., Need E.F., Tilley W., Greenberg N.M. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer 2007, 120:719-733.
21. Coetzee G.A., Ross R.K. Re: prostate cancer and the androgen receptor. J. Natl. Cancer Inst. 1994, 86:872-873.
22. Cunliffe V.T. Eloquent silence: developmental functions of class I histone deacetylases. Curr. Opin. Genet. Dev. 2008, 18:404-410.
23. Dotzlaw H., Moehren U., Mink S., Cato A.C.B., Iniguez Lluhi J.A., Baniahmad A. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol. Endocrinol. 2002, 16:661-673.
24. Edwards S.M., Badzioch M.D., Minter R., Hamoudi R., Collins N., Ardern-Jones A., Dowe A., Osborne S., Kelly J., Shearer R., Easton D.F., Saunders G.F., Dearnaley D.P., Eeles R.A. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int. J. Cancer 1999, 84:458-465.
25. Eisold M., Asim M., Eskelinen H., Linke T., Baniahmad A. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. J. Mol. Endocrinol. 2009, 42:429-435.
26. Estebanez-Perpina E., Arnold L.A., Nguyen P., Rodrigues E.D., Mar E., Bateman R., Pallai P., Shokat K.M., Baxter J.D., Guy R.K., Webb P., Fletterick R.J. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc. Natl. Acad. Sci. U S A. 2007, 104:16074-16079.
27. Fischer K., Kelly S.M., Watt K., Price N.C., McEwan I.J. Conformation of the mineralocorticoid receptor N-terminal domain: evidence for induced and stable structure. Mol. Endocrinol. 2010, 24:1935-1948.
28. Freedman M.L., Pearce C.L., Penney K.L., Hirschhorn J.N., Kolonel L.N., Henderson B.E., Altshuler D. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am. J. Hum. Genet. 2005, 76:82-90.
29. Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Brufsky A., Talcott J., Hennekens C.H., Kantoff P.W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. U S A. 1997, 94:3320-3323.
30. Glass C.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000, 14:121-141.
31. He B., Gampe R.T., Hnat A.T., Faggart J.L., Minges J.T., French F.S., Wilson E.M. Probing the Functional Link between Androgen Receptor Coactivator and Ligand-binding Sites in Prostate Cancer and Androgen Insensitivity. J. Biol. Chem. 2006, 281:6648-6663.
32. He B., Kemppainen J.A., Wilson E.M. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 2000, 275:22986-22994.
33. He B., Lee L.W., Minges J.T., Wilson E.M. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J. Biol. Chem. 2002, 277:25631-25639.
34. He B., Minges J.T., Lee L.W., Wilson E.M. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J. Biol. Chem. 2002, 277:10226-10235.
35. Heemers H.V., Tindall D.J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 2007, 28:778-808.
36. Hendriksen P.J., Dits N.F., Kokame K., Veldhoven A., van Weerden W.M., Bangma C.H., Trapman J., Jenster G. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 2006, 66:5012-5020.
37. Hodgson M.C., Astapova I., Cheng S., Lee L.J., Verhoeven M.C., Choi E., Balk S.P., Hollenberg A.N. The androgen receptor recruits nuclear receptor corepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J. Biol. Chem. 2005, 280:6511-6519.
38. Hodgson M.C., Astapova I., Hollenberg A.N., Balk S.P. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res. 2007, 67:8388-8395.
39. Hodgson M.C., Shen H.C., Hollenberg A.N., Balk S.P. Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor. Mol. Cancer Ther. 2008, 7:3187-3194.
40. Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., Ryan C., Smith S., Scher H., Scardino P., Reuter V., Gerald W.L. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 2004, 164:217-227.
41. Hsiao P.W., Lin D.L., Nakao R., Chang C. The linkage of Kennedy's neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J. Biol. Chem. 1999, 274:20229-20234.
42. Hur E., Pfaff S.J., Payne E.S., Gron H., Buehrer B.M., Fletterick R.J. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol. 2004, 2:E274.
43. Irvine R.A., Ma H., Yu M.C., Ross R.K., Stallcup M.R., Coetzee G.A. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum. Mol. Genet. 2000, 9:267-274.
44. Jackson T.A., Richer J.K., Bain D.L., Takimoto G.S., Tung L., Horwitz K.B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 1997, 11:693-705.
45. Jenster G., van der Korput H.A., Trapman J., Brinkmann A.O. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem. 1995, 270:7341-7346.
46. Jenster G., van der Korput J.A., Trapman J., Brinkmann A.O. Functional domains of the human androgen receptor. J. Steroid Biochem. Mol. Biol. 1992, 41:671-675.
47. Jepsen K., Hermanson O., Onami T.M., Gleiberman A.S., Lunyak V., McEvilly R.J., Kurokawa R., Kumar V., Liu F., Seto E., Hedrick S.M., Mandel G., Glass C.K., Rose D.W., Rosenfeld M.G. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 2000, 102:753-763.
48. Jia L., Berman B.P., Jariwala U., Yan X., Cogan J.P., Walters A., Chen T., Buchanan G., Frenkel B., Coetzee G.A. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS ONE 2008, 3:e3645.
49. Laudet V. Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor. J. Mol. Endocrinol. 1997, 19:207-226.
50. Liao G., Chen L.-Y., Zhang A., Godavarthy A., Xia F., Ghosh J.C., Li H., Chen J.D. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J. Biol. Chem. 2003, 278:5052-5061.
51. List H.J., Smith C.L., Rodriguez O., Danielsen M., Riegel A.T. Inhibition of histone deacetylation augments dihydrotestosterone induction of androgen receptor levels: an explanation for trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse mammary tumor virus promoter. Exp. Cell Res. 1999, 252:471-478.
52. Ma H., Hong H., Huang S.M., Irvine R.A., Webb P., Kushner P.J., Coetzee G.A., Stallcup M.R. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol. Cell. Biol. 1999, 19:6164-6173.
53. McEwan I. Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain. Endocr. Relat. Cancer 2004, 11:281-293.
54. McEwan I.J. Nuclear receptors: one big family. Methods Mol. Biol. 2009, 505:3-18.
55. McEwan I.J., Lavery D., Fischer K., Watt K. Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors. Nucl. Recept. Signal 2007, 5:e001.
56. McKenna N.J., O'Malley B.W. From ligand to response: generating diversity in nuclear receptor coregulator function. J. Steroid Biochem. Mol. Biol. 2000, 74:351-356.
57. Moilanen A., Rouleau N., Ikonen T., Palvimo J.J., Janne O.A. The presence of a transcription activation function in the hormone-binding domain of androgen receptor is revealed by studies in yeast cells. FEBS Lett. 1997, 412:355-358.
58. Need E.F., Scher H.I., Peters A.A., Moore N.L., Cheong A., Ryan C.J., Wittert G.A., Marshall V.R., Tilley W.D., Buchanan G. A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology 2009, 150:2674-2682.
59. O'Malley B.W., Qin J., Lanz R.B. Cracking the coregulator codes. Curr. Opin. Cell Biol. 2008, 20:310-315.
60. Ozers M.S., Marks B.D., Gowda K., Kupcho K.R., Ervin K.M., Rosier T.D., Qadir N., Eliason H.C., Riddle S.M., Shekhani M.S. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a Time-resolved fluorescence resonance energy transfer assay. Biochemistry 2007, 46:683-695.
61. Perissi V., Aggarwal A., Glass C.K., Rose D.W., Rosenfeld M.G. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004, 116:511-526.
62. Perissi V., Jepsen K., Glass C.K., Rosenfeld M.G. Deconstructing repression: evolving models of co-repressor action. Nat. Rev. Genet. 2010, 11:109-123.
63. Peterson T.J., Karmakar S., Pace M.C., Gao T., Smith C.L. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity. Mol. Cell. Biol. 2007, 27:5933-5948.
64. Pissios P., Tzameli I., Kushner P., Moore D.D. Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Mol. Cell 2000, 6:245-253.
65. Price D.K., Chau C.H., Till C., Goodman P.J., Baum C.E., Ockers S.B., English B.C., Minasian L., Parnes H.L., Hsing A.W., Reichardt J.K., Hoque A., Tangen C.M., Kristal A.R., Thompson I.M., Figg W.D. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. J. Urol. 2010, 184:2297-2302.
66. Rajender S., Singh L., Thangaraj K. Phenotypic heterogeneity of mutations in androgen receptor gene. Asian J. Androl. 2007, 9:147-179.
67. Robins D.M., Albertelli M.A., O'Mahony O.A. Androgen receptor variants and prostate cancer in humanized AR mice. J. Steroid Biochem. Mol. Biol. 2008, 108:230-236.
68. Scher H.I., Buchanan G., Gerald W., Butler L.M., Tilley W.D. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr. Relat. Cancer 2004, 11:459-476.
69. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 2005, 23:8253-8261.
70. Shen H.C., Buchanan G., Butler L.M., Prescott J., Henderson M., Tilley W.D., Coetzee G.A. GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. Biol. Chem. 2005, 386:69-74.
71. Smith C.L., Nawaz Z., O'Malley B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 1997, 11:657-666.
72. Smith S.A., McLaughlin L.W. Probing contacts to the DNA backbone in the trp repressor-operator sequence-specific protein-nucleic acid complex using diastereomeric methylphosphonate analogues. Biochemistry 1997, 36:6046-6058.
73. Stanya K.J., Kao H.Y. New insights into the functions and regulation of the transcriptional corepressors SMRT and N-CoR. Cell Div. 2009, 4:7.
74. Trtkova K., Paskova L., Matijescukova N., Kolar Z. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor. Cancer Biomark 2010, 7:79-90.
75. van Royen M.E., Cunha S.M., Brink M.C., Mattern K.A., Nigg A.L., Dubbink H.J., Verschure P.J., Trapman J., Houtsmuller A.B. Compartmentalization of androgen receptor protein-protein interactions in living cells. J. Cell Biol. 2007, 177:63-72.
76. Varlakhanova N., Snyder C., Jose S., Hahm J.B., Privalsky M.L. Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain. Mol. Cell. Biol. 2010, 30:1434-1445.
77. Veldscholte J., Berrevoets C.A., Ris-Stalpers C., Kuiper G.G., Jenster G., Trapman J., Brinkmann A.O., Mulder E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 1992, 41:665-669.
78. Veldscholte J., Voorhorst-Ogink M.M., Bolt-de Vries J., van Rooij H.C., Trapman J., Mulder E. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim. Biophys. Acta 1990, 1052:187-194.
79. Wang Q., Li W., Zhang Y., Yuan X., Xu K., Yu J., Chen Z., Beroukhim R., Wang H., Lupien M., Wu T., Regan M.M., Meyer C.A., Carroll J.S., Manrai A.K., Janne O.A., Balk S.P., Mehra R., Han B., Chinnaiyan A.M., Rubin M.A., True L., Fiorentino M., Fiore C., Loda M., Kantoff P.W., Liu X.S., Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138:245-256.
80. Wolf I.M., Heitzer M.D., Grubisha M., DeFranco D.B. Coactivators and nuclear receptor transactivation. J. Cell. Biochem. 2008, 104:1580-1586.
81. Yoon H.-G., Wong J. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol. Endocrinol. 2006, 20:1048-1060.
82. Zhang X., Jeyakumar M., Petukhov S., Bagchi M.K. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol. Endocrinol. 1998, 12:513-524.